• Acasti Pharma – pivotal Phase (3) results moment is upon us

    December 30, 2019 | Posted by

    We have covered Acasti Pharmaceuticals extensively per HERE this last 2 years and the vast majority of that coverage has been focused around the key Phase (3) so called Trilogy 1 & 2 trial results for the company’s cholesterol lowering drug – Capre – and that are due out, in the former’s case, any day […]

  • ACASTI Pharmaceuticals – countdown is on to Phase (3) trial results

    October 26, 2019 | Posted by

    We have written extensively about Acasti Pharma per HERE and it has been one of our most successful trades this year – we are effectively now “in for free” (always the best position to be in emotionally) following the near 6 fold increase from lows below 50c to near $3 at the peak in mid […]

  • Acasti Pharmaceuticals update – market finally wakes up to the potential implications of Phase 3 trials of CaPre

    July 28, 2019 | Posted by

    It has been quite the month for holders of Acasti Pharmaceuticals as the chart below pays testimony to. The stock has risen from just over $1 to a peak of $2.50 in recent days. Full background coverage by us can be found on the stock HERE. Acasti is one of our largest positions and was […]

  • Acasti Pharma – Fully funded to Phase 3 completion. Shares retain huge upside potential

    February 27, 2019 | Posted by

    By Richard Gill, CFA We have been followers of Nasdaq listed krill oil specialist Acasti Pharmaceuticals (ACST) for some time now, having last updated on the company in October last year. While the share price has shown some volatility since then, 2019 has so far been a good year for the company, with the shares […]

  • Align Research Top 10 Picks for 2019

    January 3, 2019 | Posted by

    To say that 2018 was a “trying” year is somewhat of an understatement. For many small and micro cap stocks, particularly the capital hungry ones and those where delivery by management of market expectations was non-existent or lacking, this resulted in almost decimatory declines for existing shareholders. The table below of the wipeouts suffered by […]

Loading More